Axsome Therapeutics News

Hold Rating on Axsome Therapeutics Amidst Regulatory Strategy and Commercialization Prospects

TipRanksMay 20 05:15

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Axsome Therapeutics, Inc., a biopharmaceutica

Simply Wall StMay 12 07:09

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Yahoo FinanceMay 9 05:15

Axsome Therapeutics Is Maintained at Buy by Mizuho

Axsome Therapeutics Is Maintained at Buy by Mizuho

Dow JonesMay 8 06:23

Axsome Therapeutics Price Target Cut to $106.00/Share From $109.00 by Mizuho

Axsome Therapeutics Price Target Cut to $106.00/Share From $109.00 by Mizuho

Dow JonesMay 8 06:23

Mizuho Maintains Buy on Axsome Therapeutics, Lowers Price Target to $106

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $109 to $106.

BenzingaMay 8 06:12

Mizuho Securities Adjusts Price Target on Axsome Therapeutics to $106 From $109, Maintains Buy Rating

Axsome Therapeutics (AXSM) has an average rating of buy and price targets ranging from $97 to $190, according to analysts polled by Capital IQ.

MT NewswiresMay 8 05:13

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Teleflex (TFX) and Axsome Therapeutics (AXSM)

TipRanksMay 8 03:20

Axsome Therapeutics to Present at Upcoming Investor Conferences

PDF Version NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of cent

Axsome TherapeuticsMay 7 23:00

Buy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical Trials

TipRanksMay 7 22:56

Axsome Therapeutics Price Target Cut to $125.00/Share From $127.00 by Citigroup

Axsome Therapeutics Price Target Cut to $125.00/Share From $127.00 by Citigroup

Dow JonesMay 7 12:27

Axsome Therapeutics Is Maintained at Buy by Citigroup

Axsome Therapeutics Is Maintained at Buy by Citigroup

Dow JonesMay 7 12:27

Citi: Maintains Axsome Therapeutics (AXSM.US) rating, adjusted from buy to buy rating, and adjusted the target price from $127.00 to $125.00.

Citi: Maintains Axsome Therapeutics (AXSM.US) rating, adjusted from buy to buy rating, and adjusted the target price from $127.00 to $125.00.

Zhitong FinanceMay 7 12:20

Citigroup Maintains Buy on Axsome Therapeutics, Lowers Price Target to $125

Citigroup analyst David Hoang maintains Axsome Therapeutics with a Buy and lowers the price target from $127 to $125.

Analyst UpgradesMay 7 12:17

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 7 10:17

Buy Rating Affirmed on Axsome Therapeutics Due to Strong Auvelity Sales and Promising Alzheimer's Treatment Pipeline

TipRanksMay 7 08:35

Axsome Therapeutics (AXSM) Gets a Buy From RBC Capital

TipRanksMay 7 07:06

Axsome Therapeutics Price Target Raised to $112.00/Share From $108.00 by Baird

Axsome Therapeutics Price Target Raised to $112.00/Share From $108.00 by Baird

Dow JonesMay 7 05:56

Axsome Therapeutics Is Maintained at Outperform by Baird

Axsome Therapeutics Is Maintained at Outperform by Baird

Dow JonesMay 7 05:56

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $190 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics with a Buy and maintains $190 price target.

Analyst UpgradesMay 7 05:32